Processa pharmaceuticals to present at the 2025 bio ceo & investor conference

Hanover, md., feb. 07, 2025 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (processa or the company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 bio ceo & investor conference being held february 10-11, 2025, at the new york marriott marquis.
PCSA Ratings Summary
PCSA Quant Ranking